Kelly L. Wilbur

Structural basis for GPR40 allosteric agonism and incretin stimulation

Joseph D. Ho, Betty Chau, Logan Rodgers et al. · Nature Communications · 2018 · 85 citations · Full text

A Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with a Unique in Vitro Profile and Potent Glucose and Lipid Effects in Rodent Models of Type 2 Diabetes and Dyslipidemia

Anne Reifel‐Miller, Keith A. Otto, Eric D. Hawkins et al. · Molecular Endocrinology · 2005 · 64 citations · Full text

Insulin Signaling, Metabolic Syndrome, Metabolic Signaling +17

The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)

Chafiq Hamdouchi, Steven D. Kahl, Anjana Patel Lewis et al. · Journal of Medicinal Chemistry · 2016 · 58 citations · Full text

Pharmacotherapy, Insulin Signaling, Translational Pharmacology +17

Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus

Chafiq Hamdouchi, Pranab Maiti, Alan M. Warshawsky et al. · Journal of Medicinal Chemistry · 2017 · 30 citations · Full text

Fused Heterocycles, Pharmacotherapy, Medicinal Chemistry +16